Several other brokerages also recently weighed in on AMED. BidaskClub raised Amedisys from a hold rating to a buy rating in a research note on Thursday, March 15th. Jefferies Group set a $70.00 target price on Amedisys and gave the stock a buy rating in a research note on Wednesday, February 28th. Oppenheimer upped their target price on Amedisys from $68.00 to $63.00 and gave the stock an outperform rating in a research note on Thursday, March 1st. Robert W. Baird set a $66.00 target price on Amedisys and gave the stock a hold rating in a research note on Thursday, March 1st. Finally, Zacks Investment Research raised Amedisys from a hold rating to a buy rating and set a $66.00 target price for the company in a research note on Tuesday, March 6th. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $63.18.
Amedisys stock opened at $62.74 on Monday. Amedisys has a twelve month low of $45.60 and a twelve month high of $65.91. The stock has a market capitalization of $2,131.86, a P/E ratio of 71.28, a price-to-earnings-growth ratio of 1.07 and a beta of 0.62. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.45 and a quick ratio of 1.45.
Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Tuesday, February 27th. The health services provider reported $0.56 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.58 by ($0.02). The company had revenue of $404.24 million during the quarter, compared to analyst estimates of $394.96 million. Amedisys had a net margin of 1.98% and a return on equity of 15.14%. During the same period in the previous year, the firm posted $0.44 earnings per share. equities research analysts predict that Amedisys will post 3 EPS for the current fiscal year.
Institutional investors and hedge funds have recently modified their holdings of the stock. LS Investment Advisors LLC increased its position in shares of Amedisys by 233.1% during the fourth quarter. LS Investment Advisors LLC now owns 3,564 shares of the health services provider’s stock worth $188,000 after purchasing an additional 2,494 shares in the last quarter. NorthCoast Asset Management LLC purchased a new stake in shares of Amedisys during the third quarter worth approximately $262,000. Fox Run Management L.L.C. purchased a new stake in shares of Amedisys during the fourth quarter worth approximately $269,000. Paloma Partners Management Co purchased a new stake in shares of Amedisys during the fourth quarter worth approximately $310,000. Finally, Crossmark Global Holdings Inc. purchased a new stake in shares of Amedisys during the third quarter worth approximately $341,000. Hedge funds and other institutional investors own 96.71% of the company’s stock.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.